Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies

Treatments and Outcomes of Peritoneal Surface Tumors Through a Centralized National Service (United Kingdom)

(2011) S Rout et al.   DISEASES OF THE COLON & RECTUM

A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth

(2010) Merete Thune Wiiger et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Exploring the peritoneal surface malignancy phenotype—a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models

(2010) Kjersti Flatmark et al.   HUMAN PATHOLOGY

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo

(2009) Mark S. Cohen et al.   ANNALS OF SURGICAL ONCOLOGY

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo

(2009) Y Andersson et al.   BRITISH JOURNAL OF CANCER

The melanoma specific 9.2.27PE immunotoxin efficiently kills melanoma cellsin vitro

(2009) Karianne Risberg et al.   INTERNATIONAL JOURNAL OF CANCER

Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study

(2009) Dominique Elias et al.   JOURNAL OF CLINICAL ONCOLOGY

8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer

(2008) Vic J. Verwaal et al.   ANNALS OF SURGICAL ONCOLOGY